281 related articles for article (PubMed ID: 27153558)
1. Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Chen X; Chen H; Dai M; Ai J; Li Y; Mahon B; Dai S; Deng Y
Oncotarget; 2016 Jun; 7(24):36622-36631. PubMed ID: 27153558
[TBL] [Abstract][Full Text] [Related]
2. A serum lipidomic strategy revealed potential lipid biomarkers for early-stage cervical cancer.
Cheng F; Wen Z; Feng X; Wang X; Chen Y
Life Sci; 2020 Nov; 260():118489. PubMed ID: 32976882
[TBL] [Abstract][Full Text] [Related]
3. Potential plasma lipid biomarkers in early-stage breast cancer.
Jiang N; Zhang G; Pan L; Yan C; Zhang L; Weng Y; Wang W; Chen X; Yang G
Biotechnol Lett; 2017 Nov; 39(11):1657-1666. PubMed ID: 28828718
[TBL] [Abstract][Full Text] [Related]
4. Identification of plasma lipid species as promising diagnostic markers for prostate cancer.
Chen X; Zhu Y; Jijiwa M; Nasu M; Ai J; Dai S; Jiang B; Zhang J; Huang G; Deng Y
BMC Med Inform Decis Mak; 2020 Sep; 20(Suppl 9):223. PubMed ID: 32967667
[TBL] [Abstract][Full Text] [Related]
5. A plasma lipidomics strategy reveals perturbed lipid metabolic pathways and potential lipid biomarkers of human colorectal cancer.
Shen S; Yang L; Li L; Bai Y; Cai C; Liu H
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Nov; 1068-1069():41-48. PubMed ID: 29028617
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a Novel Plasma Protein Signature for Breast Cancer Diagnosis by Using Multiple Reaction Monitoring-based Mass Spectrometry.
Lee HB; Kang UB; Moon HG; Lee J; Lee KM; Yi M; Park YS; Lee JW; Yu JH; Choi SH; Cho SH; Lee C; Han W; Noh DY
Anticancer Res; 2015 Nov; 35(11):6271-9. PubMed ID: 26504062
[TBL] [Abstract][Full Text] [Related]
7. Distinct plasma lipids profiles of recurrent ovarian cancer by liquid chromatography-mass spectrometry.
Li J; Xie H; Li A; Cheng J; Yang K; Wang J; Wang W; Zhang F; Li Z; Dhillon HS; Openkova MS; Zhou X; Li K; Hou Y
Oncotarget; 2017 Jul; 8(29):46834-46845. PubMed ID: 27564116
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive lipid profiling of plasma in patients with benign breast tumor and breast cancer reveals novel biomarkers.
Yang L; Cui X; Zhang N; Li M; Bai Y; Han X; Shi Y; Liu H
Anal Bioanal Chem; 2015 Jul; 407(17):5065-77. PubMed ID: 25651902
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer detection using targeted plasma metabolomics.
Jasbi P; Wang D; Cheng SL; Fei Q; Cui JY; Liu L; Wei Y; Raftery D; Gu H
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():26-37. PubMed ID: 30562627
[TBL] [Abstract][Full Text] [Related]
10. A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer.
Zhang L; Xu Y; Jin X; Wang Z; Wu Y; Zhao D; Chen G; Li D; Wang X; Cao H; Xie Y; Liang Z
Breast Cancer Res Treat; 2015 Nov; 154(2):423-34. PubMed ID: 26476723
[TBL] [Abstract][Full Text] [Related]
11. Plasma Levels and Diagnostic Utility of M-CSF, MMP-2 and its Inhibitor TIMP-2 in the Diagnostics of Breast Cancer Patients.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Clin Lab; 2016 Sep; 62(9):1661-1669. PubMed ID: 28164586
[TBL] [Abstract][Full Text] [Related]
12. Triple Negative Breast Cancer Detection Using LC-MS/MS Lipidomic Profiling.
Eghlimi R; Shi X; Hrovat J; Xi B; Gu H
J Proteome Res; 2020 Jun; 19(6):2367-2378. PubMed ID: 32397718
[TBL] [Abstract][Full Text] [Related]
13. Carnitine palmitoyl transferase 1A is a novel diagnostic and predictive biomarker for breast cancer.
Tan Z; Zou Y; Zhu M; Luo Z; Wu T; Zheng C; Xie A; Wang H; Fang S; Liu S; Li Y; Lu Z
BMC Cancer; 2021 Apr; 21(1):409. PubMed ID: 33858374
[TBL] [Abstract][Full Text] [Related]
14. Alterations in arginine and energy metabolism, structural and signalling lipids in metastatic breast cancer in mice detected in plasma by targeted metabolomics and lipidomics.
Kus K; Kij A; Zakrzewska A; Jasztal A; Stojak M; Walczak M; Chlopicki S
Breast Cancer Res; 2018 Dec; 20(1):148. PubMed ID: 30514398
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.
Buas MF; Gu H; Djukovic D; Zhu J; Drescher CW; Urban N; Raftery D; Li CI
Gynecol Oncol; 2016 Jan; 140(1):138-44. PubMed ID: 26521694
[TBL] [Abstract][Full Text] [Related]
16. Serum microRNA as potential biomarker to detect breast atypical hyperplasia and early-stage breast cancer.
An X; Quan H; Lv J; Meng L; Wang C; Yu Z; Han J
Future Oncol; 2018 Dec; 14(30):3145-3161. PubMed ID: 30220214
[TBL] [Abstract][Full Text] [Related]
17. A plasma metabolite panel as biomarkers for early primary breast cancer detection.
Yuan B; Schafferer S; Tang Q; Scheffler M; Nees J; Heil J; Schott S; Golatta M; Wallwiener M; Sohn C; Koal T; Wolf B; Schneeweiß A; Burwinkel B
Int J Cancer; 2019 Jun; 144(11):2833-2842. PubMed ID: 30426507
[TBL] [Abstract][Full Text] [Related]
18. Low abundance protein enrichment for discovery of candidate plasma protein biomarkers for early detection of breast cancer.
Meng R; Gormley M; Bhat VB; Rosenberg A; Quong AA
J Proteomics; 2011 Dec; 75(2):366-74. PubMed ID: 21851866
[TBL] [Abstract][Full Text] [Related]
19. Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach.
Beretov J; Wasinger VC; Millar EK; Schwartz P; Graham PH; Li Y
PLoS One; 2015; 10(11):e0141876. PubMed ID: 26544852
[TBL] [Abstract][Full Text] [Related]
20. Gangliosides profiling in serum of breast cancer patient: GM3 as a potential diagnostic biomarker.
Li Q; Sun M; Yu M; Fu Q; Jiang H; Yu G; Li G
Glycoconj J; 2019 Oct; 36(5):419-428. PubMed ID: 31297734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
